DE vs MRK: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Deere & Company · Industrials
$703.12
-12.2% upside to fair value
Med Conviction
Grade C
High Quality
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MRK has more upside to fair value
(-4.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
MRK |
| Current Price |
$703.12 |
$147.17 |
| Fair Value Estimate |
$616.99 |
$141.07 |
| Upside to Fair Value |
-12.2%
|
-4.1%
|
| Market Cap |
$189.8B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
22.1x
|
29.6x
|
| Price / Sales |
4.0x
|
5.5x
|
| Price / FCF |
49.1x
|
22.6x
|
| Revenue Growth YoY |
+7.0%
|
+5.1%
|
| Gross Margin |
35.7%
|
75.4%
|
| Operating Margin |
19.0%
|
16.7%
|
| Return on Equity |
18.1%
|
6.6%
|
| Dividend Yield |
0.92% |
2.31% |
| FCF Yield |
2.04%
|
4.42%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Deere & Company is a 1837-founded global manufacturer of agricultural, turf, and construction equipment organized across Production and Precision Agriculture, Small Agriculture and Turf, Construction and Forestry, and Financial Services, employing roughly 73,100 people under CEO John C. May. Business quality is high on franchise strength but currently strained by the large-agriculture cycle: TTM …
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
DE |
MRK |
| Zone Low |
$462.74 |
$105.80 |
| Zone High |
$524.44 |
$119.91 |
| In Buy Zone? |
No
|
No
|